NcXHF

KNAPP, DHAWAN, AND OSTRANDER
14. Fenger JM, London CA, Kisseberth WC. Canine osteosarcoma: a naturally
occurring disease to inform pediatric oncology. ILAR J. 2014;55:
69-85.
15. Bushell KR, Kim Y, Chan FC, et al. Genetic inactivation of TRAF3 in
canine and human B-cell lymphoma. Blood. 2015;125:999-1005. Epub
2014 Dec 2.
16. Ito D, Frantz AM, Modiano JF. Canine lymphoma as a comparative
model for human non-Hodgkin lymphoma: recent progress and applications.
Vet Immunol Immunopathol. 2014;159:192-201.
17. Parker HG, Shearin AL, Ostrander EA. Man’s best friend becomes biology’s
best in show: genome analyses in the domestic dog. Annu Rev
Genet. 2010;44:309-336.
18. Ranieri G, Gadaleta CD, Patruno R, et al. A model of study for human
cancer: spontaneous occurring tumors in dogs. Biological features and
translation for new anticancer therapies. Crit Rev Oncol Hematol. 2013;
88:187-197.
19. Glickman LT, Domanski LM, Maguire TG, et al. Mesothelioma in pet
dogs associated with exposure of their owners to asbestos. Environ Res.
1983;32:305-313.
20. Reif JS. Animal sentinels for environmental and public health. Public
Health Rep. 2011;126 Suppl 1:50-57.
21. Glickman LT, Raghavan M, Knapp DW, et al. Herbicide exposure and
the risk of transitional cell carcinoma of the urinary bladder in Scottish
Terriers. J Am Vet Med Assoc. 2004;224:1290-1297.
22. Knapp DW, Peer WA, Conteh A, et al. Detection of herbicides in the
urine of pet dogs following home lawn chemical application. Sci Total
Environ. 2013;456-457:34-41.
23. Waters DJ, Shen S, Glickman LT, et al. Prostate cancer risk and DNA
damage: translational signifıcance of selenium supplementation in a canine
model. Carcinogenesis. 2005;26:1256-1262.
24. Chiang EC, Shen S, Kengeri SS, et al. Defıning the Optimal Selenium
Dose for Prostate Cancer Risk Reduction: insights from the U-Shaped
Relationship between Selenium Status, DNA Damage, and Apoptosis.
Dose-Response. 2009;8:285-300.
25. Lindblad-Toh K, Wade CM, Mikkelsen TS, et al. Genome sequence,
comparative analysis and haplotype structure of the domestic dog.
Nature. 2005;438:803-819.
26. Alvarez CE. Naturally occurring cancers in dogs: insights for translational
genetics and medicine. ILAR J. 2014;55:16-45.
27. Karlsson EK, Lindblad-Toh K. Leader of the pack: gene mapping in dogs
and other model organisms. Nat Rev Genet. 2008;9:713-725.
28. Shearin AL, Ostrander EA. Leading the way: canine models of genomics
and disease. Dis Model Mech. 2010;3:27-34.
29. Karyadi DM, Karlins E, Decker B, et al. A copy number variant at the
KITLG locus likely confers risk for canine squamous cell carcinoma of
the digit. PLoS Genet. 2013;9:e1003409.
30. Lingaas F, Comstock KE, Kirkness EF, et al. A mutation in the canine
BHD gene is associated with hereditary multifocal renal cystadenocarcinoma
and nodular dermatofıbrosis in the German Shepherd dog.
Hum Mol Genet. 2003;12:3043-3053.
31. American Cancer Society. What are the key What are the key statistics
about bladder cancer? http://www.cancer.org/cancer/bladdercancer/
detailedguide/bladder-cancer-key-statistics. Accessed February 27, 2015.
32. Cancer Research UK. Bladder cancer mortality statistics. http://www.
cancerresearchuk.org/cancer-info/cancerstats/types/bladder/mortality/
uk-bladder-cancer-mortality-statistics. Accessed February 2, 2015.
33. Witjes JA, Compérat E, Cowan NC, et al. EAU guidelines on muscleinvasive
and metastatic bladder cancer: summary of the 2013 guidelines.
Eur Urol. 2014;65:778-792.
34. Yafı FA, Aprikian AG, Chin JL, et al. Contemporary outcomes of 2287
patients with bladder cancer who were treated with radical cystectomy:
a Canadian multicentre experience. BJU Int. 2011;108:539-545.
35. Balar AV, Milowsky MI. Cytotoxic and DNA-targeted therapy in
urothelial cancer: have we squeezed the lemon enough? Cancer. 2015;
121:179-187.
36. Svatek RS, Hollenbeck BK, Holmäng S, et al. The economics of bladder
cancer: costs and considerations of caring for this disease. Eur Urol.
2014;66:253-262.
37. Arantes-Rodrigues R, Colaço A, Pinto-Leite R, et al. In vitro and in vivo
experimental models as tools to investigate the effıcacy of antineoplastic
drugs on urinary bladder cancer. Anticancer Res. 2013;33:1273-1296.
38. Wu XR, Sun TT, McConkey DJ. Animal models of bladder cancer. In
Lerner, Schoenberg M, Sternberg CN, (eds). Textbook of bladder cancer.
Oxen UK: Taylor and Francis; 2006.
39. Knapp DW, McMillan SK. Tumors of the urinary system. In Withrow
SJ, Vail DM, (eds). Withrow and MacEwen’s Small Animal Clinical Oncology.
5th ed. St Louis: Elsevier-Saunders; 2013.
40. Lerner SP, Schoenberg MP, Sternberg CN, et al (eds). Textbook of Bladder
Cancer. Oxon, UK: Taylor and Francis; 2006.
41. Patrick DJ, Fitzgerald SD, Sesterhenn IA, et al. Classifıcation of canine
urinary bladder urothelial tumours based on the World Health Organization/International
Society of Urological Pathology consensus classifıcation.
J Comp Pathol. 2006;135:190-199.
42. Dhawan D, Ramos-Vara JA, Naughton JF, et al. Targeting folate receptors
to treat invasive urinary bladder cancer. Cancer Res. 2013;73:875-
884.
43. Hahn NM, Bonney PL, Dhawan D, et al. Subcutaneous 5-azacitidine
treatment of naturally occurring canine urothelial carcinoma: a novel
epigenetic approach to human urothelial carcinoma drug development.
J Urol. 2012;187:302-309.
44. Alavanja MC, Bonner MR. Occupational pesticide exposures and
cancer risk: a review. J Toxicol Environ Health B Crit Rev. 2012;15:
238-263.
45. Koutros S, Lynch CF, Ma X, et al. Heterocyclic aromatic amine pesticide
use and human cancer risk: results from the U.S. Agricultural Health
Study. Int J Cancer. 2009;124:1206-1212.
46. Singh BP, Nyska A, Kissling GE, et al. Urethral carcinoma and hyperplasia
in male and female B6C3F1 mice treated with 3,3,4,4tetrachloroazobenzene
(TCAB). Toxicol Pathol. 2010;38:372-381.
47. Burger M, Catto JW, Dalbagni G, et al. Epidemiology and risk factors of
urothelial bladder cancer. Eur Urol. 2013;63:234-241.
48. Franekova M, Halasova E, Bukovska E, et al. Gene polymorphisms in
bladder cancer. Urol Oncol. 2008;26:1-8.
49. Murta-Nascimento C, Schmitz-Dräger BJ, Zeegers MP, et al. Epidemiology
of urinary bladder cancer: from tumor development to patient’s
death. World J Urol. 2007;25:285-295.
50. Center for Cancer Research. Comparative Oncology Trials Consortium.
https://ccrod.cancer.gov/confluence/display/CCRCOPWeb/
ComparativeOncologyTrialsConsortium. Accessed February 2,
2015.
51. National Cancer Institute. The Cancer Genome Atlas. http://
cancergenome.nih.gov/. Accessed February 2, 2015.
e672
2015 ASCO EDUCATIONAL BOOK | asco.org/edbook